The grant follows GangaGen's successful completion of lead optimisation milestones within its ongoing CARB-X partnership for its 'Klebicin programme
GangaGen has secured the third instalment of its phased funding grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), the global initiative led by Boston University to support the development of antibacterial products aimed at diagnosing, preventing, and treating drug-resistant infections.
The grant follows GangaGen's successful completion of lead optimisation milestones within its ongoing CARB-X partnership for its 'Klebicin programme,' which is designed to address infections caused by multidrug-resistant Klebsiella pneumoniae.
CARB-X has already committed $7.9 million to support the pre-clinical development of GangaGen's Klebicin project. Contingent of meeting specific milestones and subject to availability of funds, further funding may be available to advance the Pre-clinical phase and demonstrate safety in human volunteers.
Tanjore S Balganesh, President, GangaGen Biotechnologies, said, "We are pleased to have met this major project milestone and delighted to receive further CARB-X funding that will enable us to take Klebicins all the way to clinics. Klebicins are protein antibacterials that specifically kill K pneumoniae, a hard-to-treat pulmonary pathogen that is highly resistant to current antibiotics".
"This would be a big step forward for the company and we are grateful to CARB-X for the continued partnership and support to develop klebicins for the treatment of pneumonia" added Vivek Daniel Paul, CSO of GangaGen Biotechnologies.
"In collaboration with CARB-X, we are committed in our efforts to fight antimicrobial resistance (AMR) and investing in novel technologies to bring transformational solutions to address this global threat," said Suchad Chiaranussati, Board Member, GangaGen Biotechnologies.